Julie Pendergast

Open enrollment across a mixed-phase pipeline

According to ClinicalTrials.gov-derived indexes, Julie Pendergast sits in the upper quartile of US sponsors by registered trial count (#3,661 of 15,742 sponsors by registered trial count).

3 total trials 2 currently recruiting 1 completed upper quartile by trial count

Julie Pendergast: 3 sponsored US clinical trials, 2 recruiting.

Julie Pendergast sponsors 3 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 1 completed. The most-studied condition in this pipeline is Postmenopausal Symptoms, with 1 trials.

Upper-quartile sponsor footprint

Julie Pendergast sits in the upper quartile of the sponsor corpus (#3,661 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

What is open in the Julie Pendergast pipeline

2 recruiting of 3 indexed (67% open); 1 completed (33%).

Phase labels are sparse on this sponsor index, so phase mix is not charted here.

Top condition: Postmenopausal Symptoms (1 trial), 2 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Julie Pendergast: open-pipeline peers nationwide

Peers matched on 3 registered trials and 67% open enrollment, not the therapeutic-area sidebar.

Julie Pendergast sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 234567 0%20%40%60%80% Total trials Recruiting share Julie Pendergast10xBio22nd Century GroupAA SecordAAADRS Clinical Research CenterAbbisko Therapeutics CoABL BioAccelerated Cure Project for Multiple SclerosisAdvanced Reconstructive Surgery Alliance
Julie Pendergast sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Julie Pendergast sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 3 trials (± recruiting share)

Sponsors near 67% open enrollment (± trial volume)

What to do with this Julie Pendergast page

3 registered trials is a research-attention snapshot, not an endorsement of Julie Pendergast or any single study.

  • 2 of Julie Pendergast's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Postmenopausal Symptoms is the condition Julie Pendergast studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Postmenopausal Symptoms trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Julie Pendergast pipeline card: 3 registered trials from official public datasets.Report a data error.